ProStrakan receives UK approval for sublingual fentanyl
This article was originally published in Scrip
Executive Summary
ProStrakenhas received a UK marketing approval for its fast-dissolving sublingual tablet, Abstral (licensed fromOrexo), in the UK, its second market. The product was launched recently in its first market, Sweden, the reference member state. Orexo received a milestone payment of $1 million following the UK marketing approval.
ProStrakenhas received a UK marketing approval for its fast-dissolving sublingual tablet, Abstral (licensed fromOrexo), in the UK, its second market. The product was launched recently in its first market, Sweden, the reference member state. Orexo received a milestone payment of $1 million following the UK marketing approval.